The introduction of prostate-specific antigen (PSA) testing for use in the early detection of prostate cancer has led to controversy about the appropriateness of prostate cancer screening and resulting treatment.
This controversy largely results from the increased costs that will result from widespread screening.
As cost control becomes a dominant concern in today's health care system, practitioners must decide whether the cost of prostate cancer screening is worth the benefits produced.
This article discusses the possible effects on total health care costs of widespread PSA screening and reviews several studies that have attempted to define the effectiveness and cost-effectiveness of PSA screening and treatment.
Mots-clés Pascal : Adénocarcinome, Prostate, Dépistage, Dosage, Taux concentration, Marqueur tumoral, Antigène spécifique tumeur, Coût, Efficacité, Amélioration, Traitement, Survie, Qualité vie, Etude statistique, Homme, Tumeur maligne, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Biologie, Economie santé
Mots-clés Pascal anglais : Adenocarcinoma, Prostate, Medical screening, Assay, Concentration factor, Tumoral marker, Tumor specific antigen, Costs, Efficiency, Improvement, Treatment, Survival, Quality of life, Statistical study, Human, Malignant tumor, Urinary system disease, Male genital diseases, Prostate disease, Biology, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0288120
Code Inist : 002B14D02. Création : 15/07/1997.